latest update:
[TrialBase DB]

trial summary · NCT06987383

Vibegron for ENergy Thinking and Resilience in Aging

Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity

Trial record from the TrialBase DB dataset, status RECRUITING, condition Obesity, sponsored by Wake Forest University Health Sciences. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06987383phase PHASE3enrollment 40start 2026-10-27

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.

Source record: https://clinicaltrials.gov/study/NCT06987383

Facts

registry idNCT06987383
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE3
study typeINTERVENTIONAL
lead conditionObesity
sponsorWake Forest University Health Sciences
sponsor classOTHER
enrollment40
start date2026-10-27
primary completion2028-07
completion2028-07
results postednot reported

Conditions

  • Obesity

Interventions

  • Vibegron
  • Placebo

Countries

  • United States

Intervention types: DRUG

Work with this record